Danaher Corp

DHR is in a Stage 2 advancing trend reinforced by an active Lockout Rally. Despite extreme overbought readings and extension above short-term EMAs, sustained institutional buying via short covering justifies immediate participation in the continuation phase while monitoring for potential rejection at longer-term resistance.

• ↑Q1 2026 revenue $6 bn (+0.5% YoY) and EPS $2.06 (+9.5%).
• ↑Bioprocessing equipment orders rose 30%, driving high-single-digit segment growth.
• ↓Q1 respiratory revenue down ~25% YoY, highlighting diagnostic pressures.